Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 7/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 7/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 7/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL811680 | 0.80 | POLB (0.41) | POLBPKMSMN1; SMN2 | |
| SCHEMBL12650279 | 0.79 | LDHA (0.40) | PKMSMN1; SMN2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL23781775 | 0.78 | CA1 (0.41) | PKMSMN1; SMN2 | |
| SCHEMBL161645 | 0.77 | CES2 (0.42) | POLBPKMSMN1; SMN2 | |
| SCHEMBL28298959 | 0.77 | POLB (0.39) | POLB | |
| SCHEMBL8357047 | 0.76 | SMN1; SMN2 (0.41) | PKMSMN1; SMN2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1703382 | 0.75 | CES2 (0.40) | POLBPKMSMN1; SMN2 | |
| SCHEMBL12544632 | 0.75 | CES2 (0.40) | POLBPKMSMN1; SMN2 | |
| Bromide SCHEMBL29086958 | 0.75 | CES2 (0.40) | POLBPKMSMN1; SMN2 | |
| SCHEMBL22358990 | 0.74 | TSHR (0.49) | PKMSMN1; SMN2TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | POLB 2094/4885PKM 685/4885SMN1; SMN2 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.